Sodium–glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials
出版年份 2021 全文链接
标题
Sodium–glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials
作者
关键词
-
出版物
ACTA DIABETOLOGICA
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-03-02
DOI
10.1007/s00592-021-01686-x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT ‐2 study): 52‐week results from a randomized controlled trial
- (2020) Chantal Mathieu et al. DIABETES OBESITY & METABOLISM
- Add‐on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study
- (2020) Torben Biester et al. DIABETES OBESITY & METABOLISM
- Non‐insulin treatments for Type 1 diabetes: critical appraisal of the available evidence and insight into future directions
- (2019) L. A. Wright et al. DIABETIC MEDICINE
- Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial
- (2019) Kohei Kaku et al. DIABETES OBESITY & METABOLISM
- Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program
- (2019) Thomas Danne et al. DIABETES CARE
- Adjunct Therapy in Type 1 Diabetes: A Survey to Uncover Unmet Needs and Patient Preferences Beyond HbA1c Measures
- (2019) Jeremy H. Pettus et al. Diabetes Technology & Therapeutics
- Effects of sodium‐glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta‐analysis of randomized controlled trials
- (2019) Jingli Lu et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials
- (2019) Giovanni Musso et al. BMJ-British Medical Journal
- Efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double‐blind, phase 3 trial
- (2019) Kohei Kaku et al. DIABETES OBESITY & METABOLISM
- Lower Renal Threshold for Glucose Reabsorption in Type 1 Diabetes Mellitus (T1DM) May Explain the Smaller Contribution of SGLT2 Inhibitors to the Improvement of Plasma Glucose Control Compared with T2DM
- (2019) Aya Osaki et al. Diabetes Therapy
- Insulin Therapy in Type 2 Diabetes
- (2019) Pablo Aschner AMERICAN JOURNAL OF THERAPEUTICS
- Dose‐dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial
- (2019) Claire Baker et al. DIABETES OBESITY & METABOLISM
- Metformin for Type 2 Diabetes
- (2019) Jayshil J. Patel et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effectiveness and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus
- (2019) Mao-Bing Chen et al. MEDICINE
- Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption
- (2019) David R Powell et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
- (2019) Marc Evans et al. Diabetes Therapy
- SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials
- (2018) Robert Puckrin et al. ACTA DIABETOLOGICA
- Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study
- (2018) John B. Buse et al. DIABETES CARE
- HbA1cand Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study
- (2018) Thomas Danne et al. DIABETES CARE
- Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial
- (2018) Chantal Mathieu et al. DIABETES CARE
- Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial
- (2018) Akira Shimada et al. DIABETES OBESITY & METABOLISM
- Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials
- (2018) Tomohide Yamada et al. DIABETES OBESITY & METABOLISM
- Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis
- (2018) Dana El Masri et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes Mellitus
- (2018) Savitha Subramanian et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
- (2018) Hiddo J.L. Heerspink et al. KIDNEY INTERNATIONAL
- Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data
- (2018) Edward W Gregg et al. LANCET
- Comparison of non-insulin antidiabetic agents as an add-on drug to insulin therapy in type 2 diabetes: a network meta-analysis
- (2018) Jeong-Hwa Yoon et al. Scientific Reports
- Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms
- (2018) P. C. Lee et al. Obesity Reviews
- Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?
- (2018) Harriet Warnes et al. Diabetes Therapy
- Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
- (2018) Mojca Lunder et al. Cardiovascular Diabetology
- Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study
- (2018) Paresh Dandona et al. DIABETES CARE
- Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
- (2018) Julio Rosenstock et al. DIABETES CARE
- Urinary glucose excretion after dapagliflozin treatment: An exposure‐response modelling comparison between Japanese and non‐Japanese patients diagnosed with type 1 diabetes mellitus
- (2018) Victor Sokolov et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes
- (2018) Hirotaka Watada et al. DIABETES OBESITY & METABOLISM
- Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989–2013: a multicentre prospective registration study
- (2018) Christopher C. Patterson et al. DIABETOLOGIA
- Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus
- (2017) John Mondick et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus
- (2017) Jian Li et al. MEDICINE
- Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
- (2017) Satish K. Garg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012
- (2017) Elizabeth J. Mayer-Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis
- (2017) Jiao Chen et al. Scientific Reports
- Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
- (2017) Paresh Dandona et al. Lancet Diabetes & Endocrinology
- Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events
- (2017) Kenneth W. Mahaffey et al. CIRCULATION
- Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis
- (2017) Jiali Liu et al. Scientific Reports
- Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials
- (2016) Matteo Monami et al. ACTA DIABETOLOGICA
- Type 1 Diabetes at a Crossroads!
- (2015) William T. Cefalu et al. DIABETES CARE
- Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
- (2015) Arthur T. Sands et al. DIABETES CARE
- Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes
- (2015) Robert R. Henry et al. DIABETES CARE
- Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry
- (2015) Kellee M. Miller et al. DIABETES CARE
- Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)
- (2015) T. R. Pieber et al. DIABETES OBESITY & METABOLISM
- Severe hypoglycemia and coronary artery calcification during the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study
- (2015) Elke R. Fährmann et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison
- (2015) J. A. McKnight et al. DIABETIC MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
- (2014) Robert R. Henry et al. DIABETES CARE
- Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial
- (2014) Bruce A. Perkins et al. DIABETES CARE
- Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
- (2014) Martin Ridderstråle et al. Lancet Diabetes & Endocrinology
- The physiology and pathophysiology of the neural control of the counterregulatory response
- (2011) Craig Beall et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Biology of Human Sodium Glucose Transporters
- (2011) Ernest M. Wright et al. PHYSIOLOGICAL REVIEWS
- External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes
- (2010) S. van Dieren et al. DIABETOLOGIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More